Analysis Ascelia Pharma: Clear path to market

Ascelia is developing a new contrast agent to improve cancer diagnotics of patients with impaired kidney function. A pivotal trial is set to start in 2019 and the prospects for success are promising, in our view.

Read the full report (Swedish) here.